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While weeks of continuous treatment is required for conventional antidepressant drugs (e.g. fluoxetine) to bring their 
full therapeutic effects, a subanesthetic dose of ketamine alleviates the core symptoms of depression (anhedonia, 
depressed mood) and suicidal thinking within just few hours and the effects may last for days. Nitrous oxide (N2O, 
“laughing gas”), another NMDAR antagonist, has recently been shown to have similar rapid antidepressant effects in 
treatment-resistant depressed patients (Nagele et al. 2015). We previously found using naïve mice ketamine and 
N2O treatment to upregulate five mRNAs related to the MAPK pathway and synaptic plasticity, both implicated as 
being important in the action of rapid-acting antidepressants. In the current study, these shared mechanisms were 
further investigated in C57BL/6JHsd mice, using behavioral test batteries to study depressive-like behaviour and 
RT-qPCR for biochemical analyses. We first aimed to demonstrate behavioral differences between naïve mice and a 
chronic corticosterone-induced animal model of depression, and to use this model to investigate antidepressant-like 
effects of ketamine and N2O. According to the results, chronic corticosterone produced some behaviors typical of a 
depressive-like phenotype, namely significant worsening of coat state and decreased saccharin consumption in the 
saccharin preference test. Both ketamine and N2O exhibited antidepressant-like effects by reverting decreased 
saccharin preference. We then aimed to elucidate the effects of ketamine and N2O on five previously found shared 
mRNAs: Arc, Dusp1, Dusp5, Dusp6 and Nr4a1. N2O significantly upregulated all targets in the vmPFC, except 
Dusp5, two hours after beginning of N2O treatment. Neither ketamine nor sole chronic corticosterone produced any 
significant changes.  
 
The results of this study suggest that N2O is a potential candidate for rapid alleviation of depressive symptoms. We 
suggest that the action of rapid-acting antidepressants, more specifically N2O, is based on a homeostatic response 
of the brain to a presented challenge. Here this challenge would be cortical excitation previously been shown to be 
caused by N2O, which leads to activation of pathways such as MAPK and subsequent Arc, Dusp and Nr4a1 
signaling. The level of expression of these markers would then depend on which phase this response is in and 
hence, the differences in time between treatment and brain sample dissection could be a reason for conflicting 
results to previous research. Future studies would benefit from detailed investigation of the chronic corticosterone-
induced model due to its potential in controlling for behavioral variability, thus reducing the number of animals 
needed for preclinical research. Overall the preliminary findings of this study could be one of the first steps in the 
search for the mechanisms underlying the potential antidepressant effect of N2O, how these molecular markers are 
related to its action and how it differs from the action of ketamine.      
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Tiivistelmä – Referat – Abstract 
 
Psykoterapia ja yleisesti käytössä olevat masennuslääkkeet vaikuttavat masennusoireisiin hitaasti, joten 
nopeavaikutteisimmille masennushoidoille on merkittävä tarve. Subanesteettinen annos ketamiinia pystyy 
lieventämään masennuksen oireita (anhedonia, masentunut mieliala) ja itsemurha-ajatuksia muutamien tuntien 
sisällä ja vaikutus voi kestää jopa muutaman päivän. Dityppioksidin (N2O, “ilokaasu”) on äskettäin osoitettu johtavan 
samankaltaiseen nopeaan masennuslääkevasteeseen (Nagele et al. 2015). Tutkimusryhmämme löysi sekä 
ketamiinin että ilokaasun lisäävän hiirissä viiden mRNA:n ekspressiota, jotka liittyvät MAPK-signalointiin ja 
synaptiseen muovautuvaisuuteen. Molemmat ovat tärkeitä nopeavaikutteisten masennuslääkkeiden toiminnalle. 
Tässä tutkimuksessa jatkettiin ketamiinin ja ilokaasun yhteisten taustamekanismien selvittämistä C57BL/6JHsd 
hiirissä, hyödyntäen käyttäytymiskokeita masennuksen kaltaisen käytöksen tarkasteluun ja RT-qPCR:ää 
biokemiallisia analyysejä varten. Ensiksi selvitimme kroonisen kortikosteronin juoton vaikutusta käyttäytymiseen, ja 
ketamiinin sekä ilokaasun kykyä muuttaa tätä. Krooninen kortikosteroni johti osittaiseen masennuksen kaltaiseen 
käyttäytymiseen, joka ilmeni turkin huonontumisella ja vähentyneellä sakkariiniliuoksen juomisella. Sekä ketamiini 
että ilokaasu palauttivat vähentyneen sakkariiniliuoksen juomisen kontrollien tasolle. Seuraavaksi lähdimme 
selvittämään ketamiinin sekä ilokaasun vaikutusta viiteen aikaisemmin löytämiimme yhteisiin mRNA-kohteisiin: Arc, 
Dusp1, Dusp5, Dusp6 ja Nr4a1. Ilokaasu lisäsi merkittävästi kaikkien muiden paitsi Dusp5 ekspressiota 
prefrontaalikorteksissa kaksi tuntia ilokaasun hoidon aloittamisen jälkeen. Kumpikaan ketamiini tai krooninen 
kortikosteroni itsessään eivät aiheuttaneet muutoksia.  
 
Tämän tutkimuksen tulokset viittaavat siihen, että ilokaasu voi olla potentiaalinen ehdokas masennuksen oireiden 
nopealle lievitykselle. Tutkielmassa ehdotetaan nopeavaikutteisten masennuslääkkeiden – tarkemmin ilokaasun – 
vaikutusten johtuvan tietynlaisesta homeostaattisesta vasteesta haasteelle. Tässä kontekstissa haasteena toimii 
aivokuoren eksitaatio, jota ilokaasun on aiemmin havaittu aiheuttavan. Eksitaatio johtaa MAPK-reitin aktivaatioon ja 
seuraavaan Arc-, Dusp- ja Nr4a1-signalointiin. Tällöin mRNA-kohteiden tasot riippuisivat siitä missä faasissa 
homeostaattinen vaste on. Näin ollen aika hoidon ja aivonäytteiden dissektion välillä voi johtaa havaittuihin 
ristiriitoihin aikaisempien tutkimusten kanssa. Tulevaisuuden tutkimukset hyötyisivät krooniseen kortikosteronin 
juottoon perustuvan masennuksen hiirimallin yksityiskohtaisemmasta tarkastelusta, koska sillä voi olla mahdollisuus 
pienentää käyttäytymisen variaatiota ja näin ollen vähentää prekliiniseen tutkimukseen vaadittavia eläinmääriä. 
Tämän tutkielman tulokset havainnollistavat ilokaasun potentiaalisten nopeiden masennuslääkevaikutusten taustalla 
olevia tekijöitä, ja sitä kuinka nämä mahdollisesti eroavat ketamiinin toiminnasta.  
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Abbreviations 
ACTH   Adrenocorticotropin hormone 
AMPAR  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
ARC   Activity-regulated cytoskeleton-associated protein 
BDNF   Brain-derived neurotrophic factor 
CORT   Corticosterone 
CRF   Corticotropin releasing factor 
CUS   Chronic unpredictable stress 
DUSP   Dual-specificity phosphatase 
ECT   Electroconvulsive therapy 
ERK   Extracellular signal-regulated kinase 
GluR   Glutamate receptor  
HPA axis  Hypothalamic-pituitary-adrenal axis 
JNK   Jun N-terminal kinase  
MAPK   Mitogen-activated protein kinase  
MDD   Major depressive disorder 
mTOR   Mammalian target of rapamycin 
N2O   Nitrous oxide (“laughing gas”) 
NMDAR  N-methyl-d-aspartate receptor 
NR4A1  Nuclear receptor subfamily 4 group A member 1 
PFC   Prefrontal cortex 
PVN   Paraventricular nucleus 
RT-qPCR  Quantitative reverse transcription polymerase chain reaction 
SPT   Saccharin preference test 
TrkB   Tropomyosin related kinase B 
TST   Tail suspension test 
ZT   Zeitgeber time  
 3 
Review of literature 
Introduction 
Major depressive disorder (MDD) is a highly prevalent and debilitating psychiatric illness. 
Common symptoms include depressed mood, anhedonia, and cognitive dysfunction 
(American Psychiatric Association, 2013). The individual’s emotional state is frequently 
dominated by negative thinking and low self-esteem, with recurring suicidal thoughts also 
being one of the hallmarks of the disease phenomenology (American Psychiatric Association, 
2013). In addition to causing vast suffering on an individual level, MDD poses a large burden 
on society. Based on worldwide studies, depression has a lifetime prevalence of 10 % to 20 %, 
affecting currently more than 260 million people worldwide. According to The Global 
Burden of Diseases, Injuries, and Risk Factors Study it was the third most leading cause of 
years lived with disability in 2017, and its ranking is not decreasing (GBD Study 2017). 
Depression and the hypothalamic-pituitary-adrenal axis 
MDD is a highly complex disorder with high comorbidity rates and diverse etiologies, hence 
unravelling the mechanisms behind it is a challenge. It is generally thought that a 
combination of genetic predisposition, psychosocial factors and alterations in 
neurotransmission and hormone levels influence the development of depression (Nestler et al., 
2002). Psychosocial factors such as exposure to stressful experiences are strongly associated 
with an increased risk for onset of depressive symptoms. This is especially the case with the 
most difficult treatment-resistant forms of depression (Kendler et al., 1999; Williams et al., 
2016). The connection between stress and depression was initially drawn from observations 
of increased activity of the hypothalamic-pituitary-adrenal (HPA) axis, elevated cortisol 
levels and disrupted cortisol rhythm in depressed patients (Linkowski et al., 1987; Nestler et 
al., 2002).  
The HPA axis is necessary for normal physiological and neurobiological responses to stress. 
One of its purposes is to prepare the body to cope with an acute stressor, and then to restore 
bodily homeostasis once the stressor has diminished.  Exposure to an acute stressor activates 
the HPA axis resulting in a cascade of endocrine events (fig. 1). This cascade includes release 
and transport of corticotropin-releasing factor (CRF) from neurons in the paraventricular 
nucleus (PVN) of the hypothalamus to the anterior pituitary, where it stimulates the release of 
adrenocorticotropin hormone (ACTH) into the circulatory system. ACTH travels to the 
adrenal glands, where it stimulates the production and release of stress glucocorticoids 
(cortisol in humans, corticosterone in rodents) from the adrenal cortex into the circulatory 
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system. Glucocorticoids act on target tissues to regulate bodily functions and mobilize energy 
to deal with the stressor. Glucocorticoids also travel to multiple regions in the brain, most 
relevantly the PVN and hippocampus, where they exert an inhibitory influence in order to 
halt HPA axis activity through a negative feedback process. Although this is a normal process, 
prolonged activation of the HPA axis can present a serious health risk, leading to 
immunosuppression, growth inhibition, sleep disorders, impaired memory, decreased sexual 
behavior and chronic dysphoria (McEwen, 1998). 
 
 
 
Figure 1.  
Schematic representation of the 
hypothalamic-pituitary-adrenal (HPA) 
axis. Neurons in the paraventricular 
nucleus (PVN) of the hypothalamus 
synthesize corticotropin-releasing factor 
(CRF), which in response to stress is 
released and transported into the anterior 
pituitary gland. This induces release of 
adrenocorticotropic hormone (ACTH) 
into the systemic circulation. ACTH 
circulates to the adrenal cortex where it 
stimulates synthesis and secretion of 
glucocorticoids, such as cortisol 
(corticosterone in rodents). 
Glucocorticoids regulate various 
metabolic events and inhibit HPA axis 
activation in a negative feedback loop.  
Elevated cortisol and the disrupted cortisol rhythmicity observed in depressed patients can be 
reversed by antidepressant treatment (Holsboer 2001; Linkowski et al. 1987). ACTH 
responses to exogenously administered CRF are also attenuated in depressed patients, with 
the relationship being most clear in depressed patients with the most severe hypercortisolism 
(Gold et al., 1986). Furthermore, patients with Cushing’s disease, a disorder marked by 
chronically high levels of cortisol, show high rates of depression (Gold et al., 1986). These 
findings provide a strong basis for the possibility that some aspects of depression may arise 
from a dysregulated HPA axis.  
Rapid-acting antidepressant ketamine 
The complexity of MDD is reflected in the inefficacy of current treatments. Depending on the 
treatment, only about 20 % to 50 % of patients demonstrate complete remission while up to 
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80 % show partial responses (Nestler et al., 2002). These treatments are also sub-optimal in 
another significant manner: time. For those patients who do respond to current treatments, 
either antidepressant drugs or psychotherapy, the therapeutic effects become evident with a 
delay of several weeks or even months (American Psychiatric Association, 2013; Nestler et 
al., 2002).Taking into consideration the association between MDD and high rates of suicide, 
this lag in therapeutic effect can be fatal. Electroconvulsive therapy (ECT) can provide more 
rapid and significant improvements in depressive behavior and it has traditionally been the 
most effective treatment form in treatment-resistant patients (Kodama et al., 2005). However, 
the use of ECT is limited by available resources and cognitive adverse effects. The interest 
for developing novel rapid-acting antidepressants reached new heights when Berman et al. 
(2000) discovered that a low-dose ketamine infusion leads to robust decreases in depressive 
symptoms already within one-to-three days in patients diagnosed with MDD.  
The neurobiological mechanisms underlying the rapid antidepressant effects of ketamine 
have not yet been fully elucidated. The current consensus is, however, that rapid facilitation 
of glutamatergic neurotransmission and subsequent activation of brain‐derived neurotrophic 
factor (BDNF) receptor tropomyosin related kinase B (TrkB) signaling in limbic brain 
structures and the consecutive increase in synaptic plasticity and synaptogenesis are 
important (Zanos et al., 2018). Notably, the behavioral effects of ketamine sustain even after 
the drug has been eliminated from the brain (Clements & Nimmo, 1981; Zanos et al., 2018), 
indicating that the underlying increases in synaptic plasticity and synaptogenesis are not only 
induced rapidly but are able to maintain persistent changes in behavior.  
Numerous mechanisms have been proposed to underlie ketamine’s rapid facilitation of 
glutamatergic neurotransmission. The most popular suggestion is that subanesthetic ketamine 
selectively blocks N-methyl-d-aspartate receptors (NMDARs) expressed on gamma 
aminobutyric acid inhibitory interneurons, which leads to lack of inhibitory feedback and a 
successive surge in glutamate and excitatory drive in the prefrontal cortex (PFC) (Autry et al., 
2011; Li et al., 2010; Zanos et al., 2018). This leads to indirect modulation of postsynaptic 
glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), 
which are integral to synaptic plasticity (Koike et al., 2011; Li et al., 2010; Maeng et al., 2008; 
Zhou et al., 2014). Additionally the further activation of BDNF receptor TrkB, mammalian 
target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) signaling along 
with the inhibition of GSK3β have all been associated with ketamine’s' antidepressant effects 
(Beurel et al., 2011; Lepack et al., 2014; Li et al., 2010; Réus et al., 2014). Pre- and co-
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treatment with a selective AMPA receptor inhibitor, 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo[f]quinoxaline-2,3-dione (NBQX), has been shown to block the induction of these 
different signaling pathways and antidepressant-like behavioral effects in rodents (Autry et al., 
2011; Li et al., 2010; Zhou et al., 2014). 
Activation of mTOR has been functionally linked with local protein synthesis in synapses, 
resulting in the production of proteins required for the formation, maturation, and function of 
new spine synapses (Li et al., 2010). Ketamine administration has been shown to transiently 
increase phosphorylation of mTOR, which led to sustained increase in the levels of synapse-
associated proteins (Li et al., 2010). This increase and the antidepressant actions of ketamine 
could be blocked with an mTOR inhibitor rapamycin, indicating that ketamine induced 
synaptogenesis and subsequent therapeutic effects occur mainly through mTOR signaling (Li 
et al., 2010). In contrast to the actions of NMDA antagonists, such as ketamine, acute or 
chronic administration of conventional monoaminergic antidepressants are proposed not to 
increase mTOR signalling (Li et al., 2010; Zanos et al., 2018), although this has not been 
thoroughly investigated.  
Nitrous oxide 
Nitrous oxide (N2O, “laughing gas”) is a widely used anesthetic and analgesic. Nagele et al. 
(2015) investigated N2O in treatment of MDD largely because its mechanism of action is 
based on inhibiting NMDA receptors like ketamine. In their Proof-of-Concept trial, 20 
patients with treatment-resistant depression were randomly assigned to either 1-hour 
inhalation of 50% nitrous oxide/50% oxygen or 50% nitrogen/50% oxygen. Compared with 
placebo, N2O significantly reduced depressive symptoms at 2 hours and 24 hours after the 
treatment. Although the primary target of N2O is the NMDA receptor, it acts on other 
receptors as well. It can cause stimulatory activity at dopaminergic, α1− and α2− adrenergic 
and opioid receptors (Banks & Hardman, 2005). Especially interaction with the opioid system 
is proposed to be the main mechanism behind its analgesic effects. N2O does not undergo 
biotransformation (in humans or mice) and its low solubility allows it to be eliminated from 
the body rapidly almost entirely via the lungs (Banks & Hardman, 2005). This extremely fast 
pharmacokinetic profile of N2O provides a unique opportunity to study the timeframe of the 
neurobiological mechanisms behind the action of rapid-acting antidepressants.  
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The MAPK pathway, depression and rapid-acting antidepressants 
One important signaling pathway shown to be necessary for not only ketamine-induced 
mTOR activation but also successive antidepressant effects is the MAPK  pathway (Gourley 
et al., 2008; Li et al., 2010; Réus et al., 2014). This cascade consists of types of protein 
kinases that are specific to the amino acids serine (Ser, S) and threonine (Thr, T). The MAPK 
family has three identified subfamilies, Jun N-terminal kinase (JNK), extracellular signal-
regulated kinases (ERKs, also known as MAPK1/3) and p38MAPK (Pérez‐Sen et al., 2019; 
Réus et al., 2014). MAPK1/3 primarily regulate cellular growth and differentiation, whereas 
p38MAPK and JNK mainly function as mediators of cellular stress (Meller et al., 2003). The 
subfamily most commonly associated with the actions of rapid-acting antidepressants is the 
MAPK1/3 family. Although, studies have suggested all three MAPK subfamilies to modulate 
AMPAR potentiation produced by the antidepressant tianeptine (Szegedi et al., 2011), 
suggesting a more extensive association between the glutamatergic system and the whole 
MAPK pathway. Shirayama et al., (2002) have shown that antidepressant effects produced by 
infusion of BDNF into the hippocampus are blocked by inhibiting the function of MAPK 
kinase, a MAPK1/3 activator. Prevention of phosphorylation of MAPK1/3 and antidepressant 
effects produced by several antidepressants has also been demonstrated with a similar 
inhibitor, PD184161, in several animal models of depression (Duman et al., 2007; Réus et al., 
2014).  
Reduced MAPK pathway activity itself has been associated with depressive behavior. It has 
been shown to be downregulated in the cortex and hippocampus of depressed humans and in 
various animal models of depression (Duric et al., 2010; Dwivedi et al., 2001; Meller et al., 
2003). Both MAPK1/3 transcription and translation, and its kinase activity were reduced in 
the PFC and hippocampus in post-mortem tissues of depressed patients and suicide victims 
compared to controls (Duric et al., 2010; Dwivedi et al., 2001). Similarly, upstream activators 
of the MAPK pathway, such as Raf kinases and MAPK kinase, were downregulated in their 
kinase activity (Duric et al., 2010). Furthermore, acute injection of PD184161 itself produces 
depressive-like effects in preclinical behavioral tests used to model depression, learned 
helplessness (LH), forced swimming test (FST) and tail suspension test (TST), although for 
TST the effect was only seen during the first three minutes not during the total six minutes of 
testing (Duman et al., 2007). These findings indicate that reduced MAPK signaling leads to 
depressive-like behavior and that activation of this signaling pathway by rapid-acting 
antidepressants such as ketamine may play a role in reversing this behavior. 
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In contrast to chronic stress, which is usually associated with MDD, preclinical studies have 
demonstrated that acute stress affects MAPK pathway activation differently. Acute restraint 
stress increased phosphorylation of MAPK1/3 in the hippocampus and PFC (including the 
cingulate cortex), whereas phosphorylation and expression of MAPK1/3 was downregulated 
in various chronic stress models of depression (Meller et al., 2003). However, the increase 
caused by acute stress was only transient, with phosphorylation levels returning to baseline 
30 minutes after termination of stress (Meller et al., 2003). Acute stress did not produce any 
effect on phosphorylated JNK and p38MAPK levels (Meller et al., 2003), whereas repeated 
restraint stress led to reduced phosphorylation of all three MAPKs although only in the PFC 
(Meller et al., 2003). The same phenomenon has been reproduced with other types of 
manipulations which are considered as forms of acute stress, such as ischemia and 
electroconvulsive shock (preclinical form of ECT; Meller et al., 2003). These results suggest 
there to be an initial widespread activation of MAPK signaling upon exposure to acute stress, 
which then diminishes after the stressor is discontinued. 
An important aspect of MAPK pathway function is its regulation by dephosphorylation. The 
specific dephosphorylation of MAPKs on both threonine and tyrosine residues is mediated by 
a subfamily of cysteine-dependent dual-specificity protein phosphatases (DUSPs) also known 
as MAPK phosphatases (MKPs) (Pérez‐Sen et al., 2019). DUSPs can control MAPK 
signaling very robustly, since they are able to deactivate MAPKs with a 10-100 times 
stronger potency than the upstream kinases (Pérez‐Sen et al., 2019). Each member of the 
DUSP family shows distinct substrate specificities for MAPKs, specific tissue distributions 
and subcellular localizations, and different modes of expression inducibility by extracellular 
stimuli (Pérez‐Sen et al., 2019). Initially mitogens activate MAPKs, which in turn promotes 
DUSP expression (Pérez‐Sen et al., 2019). Traditionally, DUSPs have been a major focus of 
cancer research due to their well-documented participation in the regulation of cell 
proliferation. However, it has been shown that expression of DUSPs is upregulated in 
depressed patients and in animal models of depression, and in preclinical studies several 
antidepressants reverse the inhibition of MAPKs observed in these same animals (Duric et al., 
2010; Gourley, Wu, & Taylor, 2008).  
Our research group has performed a study in which we observed shared effects on mRNA 
expression between subanesthetic ketamine and N2O treatments in naïve mice using mRNA 
sequencing. Some of the most significant effects shared by both treatments were seen in 
markers that play important roles in MAPK signaling (Rozov et al., unpublished data). 
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Certain Dusps were among the most affected. Interestingly, their expression was upregulated, 
just as has been shown with depressed patients and animal models of depression. The three 
most significantly upregulated Dusps were Dusp1, Dusp5 and Dusp6. In addition to these, 
ketamine and N2O upregulated Arc and Nr4a1, which can affect synaptic organization. Few 
studies have focused on how these five gene markers are affected by rapid-acting 
antidepressants in animal models of depression. Hence, they were chosen to be analyzed in 
my thesis. Next, I will give a brief introduction on these target genes and their association to 
MDD and rapid-acting antidepressants.   
Dusp1 
Depending on the cellular model and context, DUSP1 inactivates MAPK1/3, p38MAPK and 
JNK. A whole-genome expression analysis study on post-mortem hippocampal tissues 
showed significantly increased expression of Dusp1 in the hippocampal subfields of subjects 
with MDD compared to matched controls (Duric et al., 2010). In addition, increased 
hippocampal Dusp1 expression as a result of viral-mediated gene transfer in mice and rats 
causes depressive-like behaviors, and expression is also increased from chronic unpredictable 
stress (CUS). Fluoxetine (a serotonin-selective reuptake inhibitor, an antidepressant) 
attenuated this increase (Duric et al., 2010). Sustained induction of Dusp1 would lead to 
inhibition of MAPK signaling, and this inhibition has been previously demonstrated in the 
hippocampal tissue of depressed individuals who committed suicide (Dwivedi et al., 2001). 
Gourley et al. (2008b) showed that antidepressants reversed inhibition of MAPK1/3 
phosphorylation in the dentate gyrus when they produced anti-depressant effects on behavior. 
Studies demonstrating the effects of rapid-acting antidepressants on Dusp1 expression itself 
provide conflicting results. A microarray analysis study found that Dusp1 was downregulated 
in the anterior cingulate cortex of naïve mice treated with a single subanesthetic dose of 
ketamine (Orozco-Solis et al., 2017). However, electroconvulsive shock was shown to 
upregulate Dusp1 levels 1 hour after administration in the rat PFC (Kodama et al., 2005).  
Dusp1 is also a stress- and glucocorticoid-responsive immediate-early gene, which supports 
the role of stress in depression. Duric et al. (2010) studied the relationship between Dusp1 
and stress by utilizing conventional Dusp1-/- mice. These mice did not differ from wild type 
mice under baseline circumstances. However, exposure to CUS did not cause a reduction in 
sucrose consumption in these mice whereas with wild type mice a progressive, significant 
reduction was observed. This suggests that the behavior of Dusp1-/- mice are comparable to 
control in the absence of stress and are resistant to CUS-induced anhedonia. Exposure to 
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CUS decreased the amount of phosphorylation of both MAPK1/3 in wild type mice (Duric et 
al., 2010). In contrast there was no significant effect of CUS on MAPK1/3 phosphorylation 
levels in Dusp1-/- mice compared to non-stressed controls, and there were no significant 
effects on total MAPK1/3 levels under any of the conditions tested. These results indicate 
that Dusp1 is required for decreased activation of MAPK signaling, as well as depressive 
behavior such as anhedonia, in response to CUS.  
Dusp1 expression is also controlled by BDNF signaling. Three hours of treatment with 
BDNF induced DUSP1 protein expression at different developmental stages in vitro 
(Jeanneteau et al., 2010). Dusp1 mRNA is downregulated in the PFC of conditional forebrain 
bdnf-/- mice and BDNF-dependent induction of Dusp1 was blocked by pre-incubation with a 
non-selective tyrosine kinase inhibitor K252a. Dusp1 was also induced during neuronal 
excitation caused by KCl, and this response was decreased by the same inhibitor, suggesting 
that neuronal excitation leading to endogenous BDNF release and following TrkB signaling 
is needed for Dusp1 induction (Jeanneteau et al., 2010). As for the effects of Dusp1 signaling 
on synaptic plasticity, it has been shown to control the complexity of axonal branching in 
vivo and in vitro (Jeanneteau et al., 2010). The outgrowth of axons from cultured cortical 
neurons decreased upon prolonged Dusp1 overexpression from days in vitro (DIV) 1-3, 
which occurred concomitantly with the dephosphorylation of MAPK1/3, p38MAPK and JNK. 
Later, JNK was shown to be the main neuronal MAPK substrate of Dusp1 that controls 
axonal shape. The dephosphorylation of JNK led to a decrease in microtubule stability seen 
as different microtubule post-translation modifications.  
Dusp5 
Dusp5 is an inducible gene for a dual-specificity phosphatase, which specifically interacts 
with and inactivates MAPK1/3 in mammalian cells (Kucharska et al., 2009). Induction of 
Dusp5 mRNA and protein in response to growth factors is also dependent on MAPK1/3 
activation and the accumulation of DUSP5 protein is tightly regulated by rapid degradation 
(Kucharska et al., 2009). DUSP5 is phosphorylated by MAPK1/3 both in vitro and in vivo on 
three sites (Thr321, Ser346 and Ser376) within its C-terminal domain (Kucharska et al., 
2009). This interaction with MAPK1/3 and transient nature of the protein suggests that Dusp5 
functions as a part of a negative feedback mechanism to specifically control the duration and 
magnitude of MAPK activation. A study has shown Dusp5 to be downregulated by a single 
dose of ketamine in the anterior cingulate cortex of naïve mice (Orozco-Solis et al., 2017). 
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Otherwise Dusp5 has not been, to my knowledge, previously studied in the context of rapid-
acting antidepressants.  
Dusp6 
Dusp6 codes for a MAPK-specific phosphatase that can be slowly induced and is 
phosphorylated upon activation of the mTOR pathway (Bermudez et al., 2008; Pérez‐Sen et 
al., 2019). This phosphorylation is interesting, since it not only activates the protein but also 
reduces the half‐life of the phosphatase as well (Bermudez et al., 2008), indicating that it also 
has a transient nature. As with Dusp5, very little is known of the role of Dusp6 in MDD and 
rapid-acting antidepressants. In the same study by Orozco-Solis et al. (2017), Dusp6 
expression was also reduced by ketamine treatment. In contrast to this, Kodama et al. (2005) 
showed that Dusp6, like Dusp1, was upregulated in the rat PFC after electroconvulsive shock.  
Arc 
Activity-regulated cytoskeleton-associated protein (Arc) is considered a plasticity protein, 
which is coded by a member of the immediate-early gene family, a rapidly activated class of 
genes (Link et al., 1995). Synaptic activity in an NMDA receptor-dependent manner 
increases Arc mRNA expression in the rat cerebral cortex 5 minutes after stimulation and this 
may last for over 8 hours (Rial Verde et al., 2006). After induction, Arc mRNA is rapidly 
trafficked into dendrites, where it and its protein localize in active synapses (Link et al., 1995; 
Rao et al., 2006; Steward & Worley, 2001). The precise function of Arc at synaptic sites in 
unknown, but some studies show it regulates AMPA receptor trafficking (Rao et al., 2006; 
Rial Verde et al., 2006). Increased Arc expression in hippocampal CA1 pyramidal neurons 
reduced the amplitude of currents mediated by AMPARs, and this reduction is prevented by 
RNAi knockdown of Arc (Rial Verde et al., 2006). The reduction of AMPAR mediated 
currents happens through endocytosis of AMPARs containing GluR2 but not GluR1 subunits 
(Rial Verde et al., 2006). This regulation seems to be bidirectional, since inhibition of AMPA 
receptors strongly potentiated activity-dependent Arc transcription (Rao et al., 2006). Another 
important factor regulating Arc transcription is the MAPK pathway. Arc transcription has 
been shown to be dependent upon activation of the MAPK cascade (Waltereit et al., 2001). 
Furthermore, BDNF strongly elevates Arc mRNA levels and upregulates Arc protein levels 
(Rao et al., 2006), and this effect is blocked by two inhibitors of the MAPK pathway, U0126 
and PD98059 (Rao et al., 2006). Arc has been shown to be transiently upregulated by 
ketamine both in vitro and in vivo (Choi et al., 2015; Kohtala et al., 2019; Li et al., 2010), and 
by acute stress (Molteni et al., 2010). However, it has seldom been studied in relation to 
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chronic stress or other animal models of depression. Chronic mild stress caused reduction in 
Arc in the PFC and CA1 region of the hippocampus, and this reduction was present also in a 
VGLUT+/- animal model that showed depressive behavior (Elizalde et al., 2010).   
Nr4a1 
The nerve growth factor IB (NR4A1, nuclear receptor subfamily 4 group A member 1; also 
known as Nur77) is a protein that is encoded by the gene Nr4a1. It is a key regulator of 
macrophage gene expression during inflammation as shown with treatment with 
lipopolysaccharides (Pei et al., 2006). Although this is the context Nr4a1 has largely been 
studied in, it has been shown to act as an activity-dependent immediate early gene responding 
to a variety of stressors and sensory stimuli. Nr4a1 transcription-induced signaling is able to 
change the expression of target genes involved in mitochondrial functions and activate the 
AMP-activated protein kinase catabolic pathway (Jeanneteau et al., 2018). Problems in this 
processing pathway due to prolonged stress could lead to metabolic impairments such as 
excessive oxidative stress in response to environmental stimuli. Chronic stress and 
corticosterone increased activity on the transcriptional level of neuronal Nr4a1 in a mouse 
cortex compared with controls at rest (Jeanneteau et al., 2018). Nr4a1 was also upregulated in 
the hippocampus of patients with MDD in the same whole-genome microarray profiling 
study mentioned in association with Dusps (Duric et al., 2010). Additionally, qPCR showed 
higher Nr4a1 mRNA levels in the medial PFC of depressed patients compared to healthy 
subjects (Jeanneteau et al., 2018). Nr4a1 could relate to depressive behavior by affecting 
synaptic organization. Indeed, it has been shown to cause dendritic spine deterioration in vivo 
in the PFC and silencing endogenous Nr4a1 expression protected against stress- and 
corticosterone-mediated dendritic spine loss. This silencing also reduced immobility in TST 
(Jeanneteau et al., 2018), indicating that Nr4a1 function does have an effect on behavior. 
Finally, the genes encoding Nr4a family transcription factors have been shown to be 
regulated by signaling mechanisms critical for memory formation (Hawk & Abel, 2011). 
These genes also show increased expression levels after learning in multiple brain structures 
(Hawk & Abel, 2011). This along with the results on dendritic spine deterioration implies that 
Nr4a1 might be related to the mechanisms of rapid-acting antidepressants through synaptic 
plasticity regulation. An in vitro study showed that ketamine upregulated expression of 
Nr4a1 (Choi et al., 2015). Due to the little amount of research available, further investigation 
is needed to further elucidate the role of Nr4a1 and the other molecular markers in not only 
MAPK signaling but also the action of rapid-acting antidepressants. 
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Animal model of depression based on chronic exposure to corticosterone 
Studies focusing on rapid-acting antidepressants are often only performed with naïve animals. 
While these studies offer valuable insights, it is still not known for certain whether the 
neurobiological effects of rapid-acting antidepressants in naïve animals differ from those in 
animal models of depression. Many different types of rodent models of depression have been 
used and validated extensively, such as CUS or social defeat stress. A majority of these are 
based on introducing a stressor to the mice or rat for a prolonged period of time, which 
mirrors the major risk factors for development of MDD, and the behavioral consequences are 
ameliorated by antidepressants. Still, studying depression in rodents can be a difficult task. 
Not only are depressive syndromes in humans heterogeneous and their etiologies diverse, but 
important symptoms such as guilt and suicidality are impossible to reproduce in animal 
models. Another problem is the variability in behavior exhibited by animal models. For 
instance, some studies suggest repeated restraint stress and chronic mild stress produces 
changes in anxiety, depressive behavior and aggression (Duric et al., 2010; Meller et al., 2003) 
whereas others show no effect (Gregus et al., 2005). A possible cause for this variation is that 
stressful stimuli can differ in terms of their physical and psychological qualities. They are 
also quite sensitive to procedural differences between experiments, which may result in 
differing circulating corticosterone levels between rodents exposed to the same stressor. In 
addition, many animals habituate to aversive effects of these stressors when they are 
repeatedly exposed to them (Gregus et al., 2005). When the goal is to produce more robust 
and reliable behavioral symptomatology, it is desirable to avoid this kind of variation. While 
no physical or behavioral stress-induced depression-like syndrome in rodents can fully 
recapitulate the human condition, a model that produces a persistent and extensive 
endophenotype sensitive to antidepressant treatments would be a valuable tool for 
understanding the neurobiological responses to rapid-acting antidepressants.  
An animal model of depression has been suggested whereby exogenous corticosterone is 
administered over a period of weeks to months by subcutaneous injection, pellet implantation, 
osmotic pump infusion, or administration via drinking water (Gourley, et al., 2008a). 
Corticosterone, as discussed previously, is a critical mediator of stress effects on behavior, 
and chronic corticosterone administration recapitulates important aspects of the 
neuroendocrine response to prolonged stress. These animals have shown anhedonia in 
sucrose/saccharin preference tests, decreased sexual behavior, immobility in forced swim and 
tail suspension test, and decreased grooming behavior - all measures typically used to infer a 
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depressive phenotype (Gourley, et al., 2008a; Gourley, et al., 2008b; Moda-Sava et al., 2019). 
Many of the changes associated with repeated corticosterone administration can be reversed 
with antidepressant treatment (Gourley, et al., 2008b; Moda-Sava et al., 2019). In addition to 
affecting behavior, glucocorticoid exposure leads to molecular and anatomical level changes 
in the brain also seen in patients with depression. Especially the hippocampus and PFC 
express high amounts of glucocorticoid receptors, and elevated corticosterone levels have 
been suggested to lead to reduction of synapses and thereby hippocampal volume, and 
impairments in BDNF mediated signaling in the PFC (Gourley, et al., 2008a; Holsboer, 2001; 
McEwen, 1998).  
This model was chosen for my thesis because of its direct connection to the HPA axis, a 
factor consistently associated with MDD. The goal in using this model was to explore the use 
of a more straightforward approach for modeling depression thus possibly lessening 
behavioral variability and the need for large cohorts of animals in preclinical research. 
Administration of corticosterone via drinking water was chosen so that there is little to no 
stress associated with the actual process of administration of the glucocorticoid. Additionally, 
we wanted corticosterone levels to have a rhythmic nature rather than continuous stable 
administration, since this better recapitulates how endogenous corticosterone acts 
physiologically. This method of administration also provided us a simple opportunity to 
gather approximate corticosterone intake while monitoring daily water intake.  
Aims of the study 
Our research group has previously studied the effects of ketamine and N2O in naïve rodents 
(Kohtala et al., 2019). mRNA sequencing data from our group’s previous research showed 
that ketamine and N2O treatment both upregulate several mRNAs implicated in MAPK 
signaling and synaptic plasticity (Dusp1, Dusp5, Dusp6, Arc and Nr4a1; Rozov et al., 
unpublished data). This project was designed to investigate this relationship further using an 
animal model of depression. The main goal of the current study was to continue the 
exploration of shared neurobiological mechanisms between rapid-acting antidepressants - in 
this case the widely accepted ketamine and the novel rapid-acting antidepressant N2O. More 
specifically, we aimed to demonstrate behavioral and biochemical differences between naïve 
mice and a chronic corticosterone-induced animal model of depression, and to use this model 
to 1) investigate antidepressant-like effects of ketamine and N2O and 2) elucidate the effects 
of ketamine and N2O on five previously found shared gene markers.   
 15 
Methods and materials 
Animals  
Male C57BL/6JHsd mice 7 weeks old at arrival (Envigo, Netherlands) were used. Mice were 
housed in sound-proof enclosures under controlled conditions (21°C, 12-h light-dark cycle, 6 
AM lights on; Scantainers, Scanbur, Sweden) in the animal facility of the University of 
Helsinki, Finland, with free access to food and water unless mentioned otherwise. Mice were 
single-housed to ensure corticosterone drinking volumes stayed as consistent as possible 
between individuals. All treatments and behavioral tests excluding the saccharin preference 
test (SPT) were performed during the light phase (zeitgeber time, ZT 3-7). The experiments 
were carried out according to the guidelines of the Society for Neuroscience and were 
approved by the County Administrative Board of Southern Finland (License: 
ESAVI/5844/2019).  
Pilot study  
A pilot study was performed to estimate sample size and the dose of corticosterone (CORT) 
to be administered in the main study. Most previous studies have used doses of 25µg/ml or 
100µg/ml. Both doses were tested, but only the higher dose of 100µg/ml had considerable 
effects on studied parameters (fig. 5). The pilot study was also used to observe the time frame 
of progression of the phenotype. The depressive phenotype was diminished to some extent 
after a week without CORT exposure (fig. 4). Hence, for this main study CORT was 
administered for 26 days and the decision made that administration will be continued during 
behavioral experiments.  
Experimental plan 
Mice were split into four groups: no corticosterone + vehicle (NO CORT VEH, n=15), 
corticosterone + vehicle (CORT VEH, n=13), corticosterone + ketamine (CORT KET, n=14) 
and corticosterone + nitrous oxide (CORT N2O, n=15). These groups were further split into 
two different cohorts: biochemical analysis (n=4-5 for each group) and behavioral analysis 
(n=9-11 for each group). See Appendix 1 for detailed n numbers. Since the weights of mice 
were spread evenly, all mice were randomly distributed to each group. A timeline of all 
procedures can be found in figure 2 and figure 3, and each procedure is outlined in further 
sections. 
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Figure 2. Schematic representation of the experiment timeline demonstrating the timing and duration 
of experimental procedures. After 7 days of habituation, CORT administration for a total of 26 days 
was started. Weights, coat state and nest quality were measured weekly. On the morning of day 32 
mice were treated with vehicle (0.9% NaCl, i.p.), ketamine (10mg/kg, i.p.) or N2O (50%, continuous 
administration for 1 h). Brain tissue was dissected from molecular cohort two hours after beginning of 
treatment. Saccharin preference test was performed for behavioral cohort in the beginning of the dark 
phase on the same day. On the morning of day 33 mice from behavioral cohort were subjected to tail 
suspension test after which brain tissue was dissected. CORT: corticosterone, N2O: nitrous oxide.   
Corticosterone treatment 
Mice were habituated for a week before starting corticosterone treatment. Corticosterone 
(CORT; 46148-100MG, Sigma, USA) was first dissolved in 99,5% ethanol to ensure proper 
dissolution. This same method was used by Moda-Sava et al (2019), which was the main 
basis of this experiment plan. The mixture was then briefly sonicated and vortexed 
sufficiently to ensure corticosterone was properly dissolved. This CORT-ethanol solution was 
dissolved in animal facility provided tap water, so that the final concentration of ethanol was 
1% and final concentration of CORT was 100µg/ml.  
Mice were exposed to either CORT solution or 1% ethanol as control in place of drinking 
water for 26 days (fig. 2). Solutions were presented to mice in two 15 ml falcon tubes, with 
tips cut to a size which allowed drinking but prevented leakage. The weight of the drinking 
tubes was recorded daily at a similar time (ZT 5-7) in order to monitor daily drinking 
volumes of each mouse. To account for potential CORT degradation, all solutions were 
replaced with fresh ones every three days.  
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Drug treatments 
Ketamine-HCl (Ketaminol®, Intervet International B.V., 511485) was diluted in 
physiological saline (0.9 % NaCl) solution and injected intraperitoneally (i.p.) 10mg/kg with 
an injection volume of about 10 ml/kg. This is a commonly used subanesthetic dose of 
ketamine associated with rapid antidepressant action in mice (Kohtala et al., 2019; Li et al., 
2010; Moda-Sava et al., 2019) and the dose used in our previous mRNA sequencing study. 
Physiological saline was used for vehicle injections. Mice for biochemical analyses were 
dissected two hours after injection and those for behavioral analyses were dissected about 24 
hours after injection (fig. 3).  
Livopan®, a 50% nitrous oxide and 50% oxygen gas mixture (112115, AGA, Finland) was 
administered into airtight plastic chambers (width x length x height): 13x15x12 cm for 1 hour 
at a flow rate of 7 l/min. This concentration and duration of treatment was used in our 
previous mRNA sequencing study and the clinical study by Nagele et al., (2015). 
Physiological saline injections were also given intraperitoneally to the group treated with 
N2O in order to control for effects of injection itself. Mice for biochemical analyses were 
dissected two hours after start of treatment and those for behavioral analyses were dissected 
about 24 hours after start of treatment (fig. 3).   
 
Figure 3. Schematic representation of the timeline for day 32 detailing vehicle, ketamine and N2O 
treatment and molecular cohort dissection. Mice were treated with vehicle (0.9% NaCl, i.p.), ketamine 
(10mg/kg, i.p.) or N2O (50%, continuous administration for 1 h) between 9 AM and 12 PM (ZT 3-6). 
Brain tissue was dissected from molecular cohort two hours after injection/beginning of treatment, 
between 11 AM and 1 PM (ZT 5-7). 
Body weight and coat state assessment 
Mice were weighed weekly at the same time of bedding change in order to avoid unnecessary 
stress and discomfort. This opportunity was also used to simultaneously assess their coat 
condition. The scoring of coat state was carried out by the assessment of eight different body 
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parts: head, neck, dorsal coat, ventral coat, tail, forepaws, hindpaws and genital region. A 
score of either 0 for a coat in a good state or a score of 1 for a dirty and unkempt coat were 
given for each of these areas. The total score for an individual mouse was obtained from the 
sum of the score of each of its body parts (Surget & Belzung, 2008). A mouse not showing a 
depression-like phenotype is assumed to exhibit normal grooming activity and thus a net coat 
condition with a low score, and vice versa. 
Saccharin preference test 
SPT examines the animal’s motivation to experience hedonic pleasure evoked by sweet 
solutions (Klein, 1974). Since anhedonia is a hallmark symptom of MDD, drinking low 
volumes of saccharin compared to water indicates a depressive-like phenotype. Saccharin 
was chosen instead of sucrose due to saccharin having no caloric value, hence controlling for 
energy intake. Mice had been habituated to the presence of drinking tubes. On test day, 
drinking of the mice was restricted for eight hours (ZT 5:30-12:30) prior to testing. Saccharin 
solution was prepared immediately before testing, by dissolving saccharin sodium salt 
hydrate (S1002-500G, Sigma, USA) in standard animal facility drinking water to make 0.1% 
(w/v) solution. The mice were then given saccharin solution in one tube and water in the 
other tube for four hours (from ZT 12:30-16:30). At the end of this period, the tubes were 
taken away and experimental solutions were returned to mice. Water consumption and 
saccharin solution consumption were calculated by weighing the tubes before and after the 
four-hour testing period. Saccharin preference was determined by calculating the fraction (%) 
of saccharin water consumption divided by total water consumption.  
Tail suspension test 
Immobility in TST is a typical measure of behavioral despair modified by long-term 
administration of CORT and chronic stress (Moda-Sava et al., 2019). Latency to first bout of 
immobility in TST is sometimes used in addition to total immobility time as a co-indicator of 
depressive behavior. Its use is based on the same assumption of immobility being an 
expression of lack of escape related behavior. Mice with a depressive phenotype should “give 
up” quicker, hence have a shorter latency to their first immobility bout. Each mouse was 
brought into the test room for 30 minutes of acclimatization before the start of its test. Mice 
were recorded with Ethovision XT (Noldus, Netherlands) for 6 minutes while suspended 
from their tail 15 cm from the top of a compartment measuring 30 cm in height using lab tape. 
A small plastic tube was placed around the base of the tail to prevent tail climbing. The 
behavioral apparatus was first thoroughly cleaned with 70% ethanol and then water between 
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animals. Frame-wise changes in coordinates of a center of gravity were used as a proxy of 
subject’s activity. To remove high frequency noise activity, data were off-line filtered by FIR 
low-pass filter (length: 5*sampling rate, cut-off: 0.5 Hz, transition: 0.5 Hz, attenuation: 60 dB) 
followed by normalization and assessment of total immobility time and latency by means of a 
custom-made Matlab routine (MathWorks, Nattick, USA).  
Nest assessment 
Impaired nest building is used as a measure of apathy, a deficit in goal-directed behavior, or 
disturbance in general activity in daily-living behavior (Planchez et al., 2019). A new nestlet 
was given to each mouse once a week along with bedding change. The quality of the nest 
built was assessed on a scale of 1-5 (1: untouched nestlet, 5: normal nest) weekly. A mouse 
not showing a depression-like phenotype is assumed to exhibit normal nest building activity.  
Brain sample collection 
Animals were euthanized at indicated times after treatment by rapid cervical dislocation 
followed by decapitation. No anesthesia was used due to its potential confounding effects on 
the analyses (Kohtala & Rantamäki, 2019). Bilateral medial prefrontal cortices and bilateral 
hippocampi were rapidly dissected on a cooled dish and stored at -80°C. The biochemical 
analyses in this project were conducted for the vmPFC, which was used for our previous 
mRNA sequencing study and is known to be an important region in the regulation of 
emotional behavior. 
Quantitative RT-PCR 
Total RNA of the samples was extracted using TRIzol reagent (15596018, Thermo Fischer 
Scientific, USA) according to manufacturer instructions with slight modifications. Frozen 
tissue was homogenized immediately after TRIzol addition and samples were kept at room 
temperature for 5 minutes to promote dissociation of nucleoprotein complexes. Chloroform 
(C2432, Sigma-Aldrich, USA) was added and the samples were vortexed for 15 seconds. 
Samples were again kept at room temperature for 5 minutes, after which they were 
centrifuged at 12,000 g for 15 minutes at 4°C. After centrifugation, all downstream 
preparation were performed on ice. The upper, aqueous phase containing the RNA was 
transferred to new tubes and isopropanol (AL03152500, Scharlau, Spain) was added for RNA 
precipitation. Samples were vortexed and incubated on ice for 10 minutes. After another 10-
minute centrifugation at 12,000 g at 4°C, the supernatant was discarded carefully while 
leaving the RNA pellet at the bottom of the tube. The RNA pellet was washed twice with 1 
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ml of 75% ethanol and centrifuged at 12,000 g for 10 min at 4°C. Supernatant was once again 
carefully removed and the pellet left to air-dry for 5 minutes. The RNA pellet was dissolved 
in 30 µl of RNAse-free water, and carefully mixed by tapping the tube. The dissolved RNA 
was incubated in a heat block (Thermo Scientific, USA) set at 60°C for 10 minutes.  
The concentration and purity of RNA was assessed with a Nanodrop 2000 Spectrophotometer. 
RNA samples with concentration > 100ng/µl, 260/280 ratio > 1.7 and 260/230 ratio > 1.8 
were reverse-transcribed using the Maxima First Strand cDNA Synthesis Kit with dsDNase 
mix (K1672, Thermo Scientific, USA). Volume containing 1 µg of RNA was added to 
nuclease-free water so that the total volume was 12 µl for each sample. The same was done to 
an extra four random samples for future dilution series and control (no reverse transcriptase, 
NoRT) preparation. Master mixes were prepared for all samples containing reverse 
transcriptase (RT) and standards by combining the 5X Reaction Mix (contains reaction buffer, 
dNTPs, oligo(dT)18 and random hexamer primers), Maxima Enzyme Mix (contains the 
reverse transcriptase and RNase inhibitor) and nuclease-free water. Only 5X Reaction Mix 
and nuclease-free water was added to the NoRT sample. All samples were mixed and 
centrifuged briefly. RT Master Mix was then added to all RT samples, mixed and centrifuged. 
All samples were incubated for cDNA synthesis in a T100 Thermal Cycler (Bio-Rad, USA) 
according to the following: 10 minutes at 25°C (random hexamer primers annealing), 30 
minutes at 55°C (oligo(dT)18 primers annealing and cDNA synthesis) and finally 5 minutes 
at 85°C (inactivation of reaction).  
The cDNA was then prepared to be quantified using real-time PCR. Samples were diluted 
1:10 and a dilution series was prepared from the extra three samples mentioned before. RT-
PCR Master Mixes were prepared from the Maxima SYBR Green/ROX qPCR Master Mix 
(2X) (K0221, Thermo Scientific, USA) by combining 2X Maxima SYBR Green qPCR 
Master Mix, 10 µM Forward primer, 10 µM Reverse primer and nuclease-free water so that 
the final volume was 6 µl for each well used. The primers used to amplify specific cDNA 
regions of the transcripts are shown in Table 1. Primers for Dusp1, Dusp5, Dusp6 and Nr4a1 
were designed de novo and characterized for selectivity and specificity. DNA amplification 
reactions were run in triplicates. After pipetting the RT-PCR Master Mix into a 384-well 
plate, 2 µl of diluted cDNA templates were added into each well. 2 µl of nuclease-free water 
was added instead of cDNA templates in the well for a second control (no-template control). 
A clear Microseal Film was applied to the plate and it briefly centrifuged. RT-PCR was 
performed for 45 cycles on the Lightcycler® 480 System (Roche, Germany). Relative 
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quantification of template was performed by calculating Cq values using the second 
derivative and dilution series method, with cDNA data being normalized to the Gapdh and ß-
actin levels. 
Table 1. Primers used for quantitative RT-PCR. 
Gene Forward primer (5’→3’) Reverse primer (5’→3’) References 
Gapdh GGTGAAGGTCGGTGTGAACGG CATGTAGTTGAGGTCAATGAAGGG (Karpova et al., 2010) 
β-actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 
Primer bank ID 6671509a1 
Arc AAGTGCCGAGCTGAGATGC CGACCTGTGCAACCCTTTC 
Primer bank ID 9055166a1 
Dusp1 GGGAGAGTGTTTGTTCATTGCC TCTGCTTCACAAACTCAAAGGC Rozov et al., unpublished 
Dusp5 CAACTTTGGCTTCATGGGACAG AGGGCTCAGTGTCTGTAAATGG Rozov et al., unpublished 
Dusp6 ACAAAACTGGGCACCTTCATTC TAGGGAAAGCGACACAGAAGTC Rozov et al., unpublished 
Nr4a1 GGGAGTGTGCTAGAAGGACTG AGCTTGAATACAGGGCATCTCC Rozov et al., unpublished 
 
Statistical Analyses 
Pilot study 
Pilot study data are presented as either median ± SD or box plots with median, interquartile 
range, and minimum and maximum values. All statistics were calculated using R software 
(version 3.5.2). Data were examined for outliers either with Grubb’s test or Dixon’s test 
depending on whether they fit assumptions of normality or not. Due to the data violating 
assumptions for parametric analyses, differences in coat state scores and saccharin preference 
were determined by Kruskal–Wallis test followed by Dunn's Multiple Comparison post-hoc 
test with Bonferroni correction if significant. Immobility in TST results were analyzed by 
univariate one-way ANOVA. P values <0.05 were considered to be statistically significant.   
Main study 
Main study data are presented as box plots with median, interquartile range, and minimum 
and maximum values. All statistics were calculated using R software (version 3.5.2). Data 
were examined for outliers either with Grubb’s test or Dixon’s test depending on whether 
they fit assumptions of normality or not. Only one value in SPT main study results was 
deemed an outlier, but its removal did not change significance of results, hence it was 
included in the analysis. Differences among experimental groups in qPCR analysis were 
determined by one-way analysis of variance (ANOVA), followed by Tukey post-hoc test 
with Bonferroni correction if ANOVA was significant. Differences among experimental 
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groups in behavioral tests were determined by either Kruskal–Wallis test or one-way 
multivariate ANOVA (MANOVA). Due to the data violating assumptions for parametric 
analyses, differences in coat and nest assessment were determined by Kruskal–Wallis test 
followed by Dunn's Multiple Comparison post-hoc test with Bonferroni correction if 
significant. A one-way MANOVA was conducted for the continuous numerical data to test 
the hypothesis that there would be one or more mean differences between experimental 
groups (independent variables, IVs) and different behavioral test results (dependent variables, 
DVs). This was followed by univariate one-way ANOVAs in order to determine how each 
dependent variable differs for the independent variable. Finally, if the effect was found to be 
significant, this was followed by Tukey post-hoc test with Bonferroni correction. P values 
<0.05 were considered to be statistically significant.  
Results 
Pilot study 
A pilot study was performed to observe whether chronic oral corticosterone administration 
produces depressive behavior. A mouse not showing a depressive-like phenotype is assumed 
to exhibit normal grooming activity and thus a net coat condition with a low score. The 
increase in coat score after 25 days of higher dose CORT administration [H (3) = 10.51, p = 
0.0006; NO CORT vs. CORT HIGH p = 0.0036, fig. 5a] therefore indicates an unkempt coat 
and possibly one manifestation of depressive behavior. Coat state worsened gradually as 
CORT administration progressed, with CORT HIGH group scores increasing to a larger 
extent compared to NO CORT or CORT LOW group (fig. 4a). Coat state started 
progressively but slowly reverting to baseline when CORT administration was stopped after 
26 days. A similar phenomenon occurred with saccharin preference, wherein one week of 
CORT administration was not enough to produce observable differences but after that 
saccharin preference was progressively reduced in the CORT HIGH group (fig. 4b). After 24 
days of CORT administration, saccharin preference was significantly reduced in the CORT 
HIGH group [H (3) = 7.768, p = 0.0117; NO CORT vs. CORT HIGH p = 0.0172, fig. 5b]. 
This indication of anhedonia was also reverted after CORT administration ended (fig. 4b). 
TST was performed after 26 days of CORT administration. Immobility duration seemed to be 
increased after the higher dose of CORT, but possibly due to high variability in results of 
both control and CORT LOW groups, this increase was not significant [F (2, 12) = 2.160, p = 
0.1580, fig. 5c]. TST was not repeated after the week of CORT withdrawal due to possible 
habituation affecting the reliability of results. 
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Figure 4. Chronic administration of a higher dose (100µg/ml) of CORT caused a progressive 
deterioration of coat state and reduction in saccharin preference during the pilot study. (A) 
Progression of coat state score during and after CORT administration phase. (B) Progression of 
saccharin preference at the beginning of the dark phase during and after CORT administration phase. 
Data depicted as median ± SD. NO CORT: control group, CORT LOW: corticosterone 25µg/ml, 
CORT HIGH: corticosterone 100µg/ml.  
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Figure 5. Chronic administration of a higher dose (100µg/ml) of CORT led to significant worsening 
of coat state and decreased saccharin preference, but not to changes in immobility during the pilot 
study. (A) Coat state score after 25 days of CORT administration. (B) Saccharin preference after 24 
days of CORT administration. (C) Total immobility time in TST at the end of CORT administration 
phase (after 26 days of CORT). Boxplots depict the median, interquartile range, and minimum and 
maximum. Compared to control group (NO CORT) = *<0.05, **<0.01 (for detailed statistical 
analyses and n numbers see Appendix 1). NO CORT: control group, CORT LOW: corticosterone 
25µg/ml, CORT HIGH: corticosterone 100µg/ml, TST: tail suspension test. 
Main study  
In order to test the hypothesis that there would be one or more mean differences between 
different behavioral test parameters and experimental groups, a MANOVA analysis was 
conducted on those main study results which fit assumptions of parametric testing. According 
to the analysis, CORT administration and/or treatments lead to a change in the combined 
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behavioral phenotype consisting of saccharin preference, duration of immobility in TST and 
latency to immobility in TST [Pillai’s Trace = 0.65, F (3,35) = 3.23, p = 0.0017]. Therefore, 
univariate one-way ANOVAs were performed in order to determine which experimental 
variables caused changes in which behavioral parameters.  
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Figure 6. The effects of chronic CORT administration and ketamine or N2O treatment on the 
behavioral phenotype of C57BL/6JHsd mice in the main study. (A) Total body weight change of mice 
from the beginning of the experiment to right before treatment. (B) Nest assessment before treatment. 
(C) Coat assessment 24 h after treatment. (D) Saccharin preference during the start of the dark phase 
on the same day as treatment. (E) Total immobility time in TST 24 h after treatment. (F) Latency to 
the first bout of immobility in TST 24 h after treatment. Treatments consisted of vehicle (0.9% NaCl, 
i.p.) or ketamine (10mg/kg, i.p.) injection or continuous administration of N2O (50%) for 1 h. 
Boxplots depict the median, interquartile range, and minimum and maximum. Compared to control 
group (NO CORT VEH) = *<0.05, **<0.01, ***<0.005, ****<0.001. Compared to CORT VEH = 
##<0.01 (for detailed statistical analyses and n numbers see Appendix 1). N2O: nitrous oxide, TST: 
tail suspension test.  
No clear impact of chronic exogenous corticosterone administration on body weight 
A change in body weight is considered one possible symptom of depression. No clear 
relationship between body weight and depression exists however, as exemplified by the 
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inconsistent results of previous clinical and preclinical research (American Psychiatric 
Association, 2013; Planchez et al., 2019). In this study, body weight was not measured after 
ketamine or N2O treatments; hence this comparison of body weight changes shows only the 
effect of chronic CORT administration on body weight. Total body weight mostly increased 
in all experimental groups during the study (fig. 6a). Kruskal-Wallis analysis implicated that 
CORT caused a significant increase in body weight [H (4) = 11.494, p = 0.0093]. However, 
Dunn’s post hoc analysis with Bonferroni correction showed a significant increase in body 
weight only between the control group and CORT KET group (p = 0.0108). No clear effect 
of chronic CORT on body weight could therefore be deduced. 
Chronic corticosterone produces some behaviors of a depressive-like phenotype  
In order to test whether chronic oral administration of CORT produces depressive-like 
behavior, we implemented tests measuring behavioral symptoms of depression such as lack 
of self-care and anhedonia. Nest assessment showed no significant differences between any 
groups [H (4) = 2.61, p = 0.4551, fig. 6b], suggesting that chronic CORT does not affect nest 
building activity. Conversely, coat state was clearly worsened indicated by increased scores 
in CORT administered groups [H (4) = 25.24, p < 0.0001, fig. 6c]. Furthermore, Dunn’s post 
hoc analysis with Bonferroni correction revealed significant increases in coat state scores 
between the control group and all three CORT treated groups (CORT VEH vs. control p =   < 
0.0001, CORT KET vs. control p = 0.0017, CORT N2O vs. control p = 0.0005). Hence, 
chronic CORT worsened coat state indicating lack of grooming and consequently a 
manifestation of a depressive-like phenotype. This was not, however, reversed by neither 
ketamine nor N2O treatment. 
Reduced saccharin preference depicts another form of depressive-like behavior. ANOVA 
analysis of saccharin preference results depicted significant changes caused by CORT 
administration and/or treatments [F (3, 35) = 8.001, p = 0.0003]. Tukey post hoc analyses 
with Bonferroni correction showed a significant decrease in saccharin preference between the 
control group and CORT VEH group (p = 0.0004, fig. 6d). This decrease was significantly 
reverted by both ketamine and N2O treatments (CORT KET vs. CORT VEH p = 0.0039, 
CORT N2O vs. CORT VEH p = 0.0046), suggesting that both treatments produced 
antidepressant-like effects.  
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Neither chronic corticosterone, ketamine nor N2O produced significant changes in lack 
of escape-related behavior in the tail suspension test  
Duration of immobility in TST is expected to be increased and latency to immobility 
decreased in a depressive-like phenotype. In this study, ANOVA analysis of total immobility 
time in TST indicated a significant difference between groups [F (3, 35) = 3.119, p = 0.0383]. 
However, Tukey post hoc analyses after Bonferroni correction did not show any significant 
differences between groups (fig. 6e). Similarly, latency to immobility did not show any 
significant differences between groups, as tested by ANOVA analysis [F (3, 35) = 2.719, p = 
0.0593, fig. 6f]. Hence this form of depressive behavior was not clearly produced by chronic 
CORT, and no conclusions regarding rescue of this behavior could be made.  
N2O treatment increased both Dusp1 and Dusp6, but not Dusp5 mRNA expressions  
ANOVA analysis of both Dusp1 and Dusp6 implicated a significant change in mRNA 
expression in the vmPFC between experimental groups [F (3, 14) = 4.260, p = 0.0247 and F 
(3, 14) = 4.277, p = 0.0244 respectively]. Tukey post hoc analyses with Bonferroni correction 
showed that N2O significantly increased both Dusp1 (CORT VEH vs. CORT N2O p = 0.0323, 
fig. 7a) and Dusp6 expression (NO CORT VEH vs. CORT N2O p = 0.0290, fig. 7c). No other 
comparisons, notably not even between CORT VEH and control, showed significant 
differences (fig. 7). No significant changes in Dusp5 expression were observed (fig. 7b).  
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Figure 7. Levels of Dusp1 (A), Dusp5 (B) and Dusp6 (C) mRNA in the vmPFC 2 h after vehicle (0.9% 
NaCl) or ketamine (10mg/kg, i.p.) injection, or start of N2O treatment (50%, continuous 
administration for 1 h) relative to control group. Boxplots depict the median, interquartile range, and 
minimum and maximum. Compared to control group (NO CORT VEH) = *<0.05. Compared to 
CORT VEH = #<0.05 (for detailed statistical analyses and n numbers see Appendix 1). vmPFC: 
ventromedial prefrontal cortex, N2O: nitrous oxide.  
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Arc and Nr4a1 mRNA expressions were increased by N2O treatment 
ANOVA analyses of Arc and Nr4a1 suggested a significant change between experimental 
groups [F (3, 14) = 4.105, p = 0.0277 and F (3, 14) = 4.904, p = 0.0156 respectively]. Tukey 
post hoc analyses with Bonferroni correction showed a significant increase of both targets 
after N2O treatment (NO CORT VEH vs. CORT N2O: Arc p = 0.0321 and Nr4a1 p = 0.0182), 
but no other significant differences were observed (fig. 8). The increases produced by N2O 
treatment were very large with some samples, even threefold or fourfold, but the significance 
was diminished by variability in the group. As with Dusps (fig. 7), chronic CORT 
administration did not seem to produce any changes in amount of Arc and Nr4a1 mRNA (fig. 
8).  
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Figure 8. Levels of Arc (A) and Nr4a1 (B) mRNA in the vmPFC 2 h after vehicle (0.9% NaCl, i.p.) 
or ketamine (10mg/kg, i.p.) injection, or start of N2O treatment (50%, continuous administration for 1 
h) relative to control group. Boxplots depict the median, interquartile range, and minimum and 
maximum. Compared to control group (NO CORT VEH) = *<0.05 (for detailed statistical analyses 
and n numbers see Appendix 1). vmPFC: ventromedial prefrontal cortex, N2O: nitrous oxide.    
Discussion 
One goal of this study was to explore the use of an animal model of depression induced by 
chronic oral administration of corticosterone. The results show a clear distinction between the 
depressive and control phenotype groups in both SPT and coat assessment. The decrease in 
saccharin preference exhibited by the CORT VEH group can be considered an indication of 
anhedonia, which is regarded as a key symptom of depressive behavior, in both animal 
models and humans. An unkempt coat condition is used as a hallmark of depressive behavior 
in animal models (Surget & Belzung, 2008). This also makes sense, because it has 
exceptional translational value – i.e. the same phenomenon, lack of self-care, can be seen in 
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many patients with MDD. The progressive worsening of coat state observed in the pilot study 
(fig. 4) exemplifies the time-dependent nature of the phenotype. Even though coat state is a 
widely used indicator of depression-like behavior, this study shows it is not necessarily the 
best parameter for studying efficacy of rapid-acting antidepressants. CORT treatment 
worsened coat condition, but this was not rescued by either treatment. A possible explanation 
why these treatments did not reverse the state of coat lies in the fact that coat state is a 
physical parameter that worsens over time. Consequently, it might not be possible for coat 
state to return to baseline in such a time frame even if grooming behavior is normalized. In 
experiments conducted with traditional antidepressants, coat state changes on average only 
after two weeks of treatment. A glyoxylase 1 inhibitor, which regulates levels of cytotoxic 
glycolysis byproducts and has been proposed to act as a rapid-acting antidepressant, reversed 
deterioration of coat state in 5 days (McMurray et al., 2018). Whether this is due to the nature 
of these antidepressants or the fact that it is simply not possible to rescue coat state in a 
shorter time period is uncertain. The results of our pilot study also demonstrated this. After 
the termination of CORT administration, coat state started improving but this change was 
slow, and even after 10 days none had reverted to baseline condition. A solution to this could 
be the use of splash test in addition to basic coat assessment. In a splash test 10 % sucrose 
solution is squirted on the dorsal coat of mice and because of the solution’s viscosity, it 
dirties the mouse fur and provokes grooming behavior (Surget & Belzung, 2008). The latency 
to initiate grooming behavior as well as the frequency and the duration of grooming in five 
minutes is measured. This presents direct information about the actual act of grooming and 
not just the result of it.  
Another goal of this study was to investigate the extent of antidepressant-like effects of 
ketamine and N2O. Both N2O and ketamine’s ability to reverse anhedonia observed in SPT 
performed less than 12 hours after treatment can be considered a rapid antidepressant effect. 
There were no significant differences in immobility nor latency to immobility in TST 
between groups after post hoc comparisons. One would expect duration of immobility to 
increase and latency to immobility decrease after chronic CORT administration, and for these 
changes to be brought back to baseline after ketamine or N2O treatment. TST is often used to 
screen for antidepressant drugs, which is why it is quite unexpected that no significant 
differences were observed between any experimental groups. Unfortunately, the variance in 
both immobility and latency to immobility results was rather large, which could partly 
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explain why no significant results were reached. Nonetheless, this means no confident 
conclusions can be made concerning this aspect of depressive-like behavior.  
Most interestingly, ketamine clearly produced a significant antidepressant effect in SPT, but 
its effect in TST was even less clear than that of N2O. Previous studies have shown that 
ketamine has lasting antidepressant effects measured by TST at 24 hours after treatment 
(Moda-Sava et al., 2019), which contradicts our results. The results of TST generally were a 
lot more varying compared to SPT, which could partially explain this discrepancy. The 
method might be more vulnerable to small fluctuations such as physiological stress reactions 
to injections between individual mice. The way TST raw data was processed may also have 
affected the results. In our pilot study, chronic administration of the same dose of CORT 
(100µg/ml) produced a clearer increase in immobility time, although this also was not 
significant (fig. 5c). In the pilot study, we used Ethovision-processed data for statistical 
analysis, whereas here we processed the raw data ourselves (see Methods) due to the 
presence of high frequency noise in the data provided by Ethovision. Even so, we did choose 
five mice at random to score manually and compared those observations to the results 
calculated from our processed data. Immobility times and latencies were higher than when 
observed manually, but the differences stayed consistent between mice. More importantly, 
the reliability of TST results in this main study is undermined by the fact that no general 
locomotor activity was recorded. Baseline locomotor activity can greatly influence 
immobility in TST, which can lead to falsely observed or false lack of differences between 
groups. Finally, one notable factor that could contribute to variation in behavioral results is 
the time between rapid-acting antidepressant treatment and behavioral testing, and possibly 
even time of treatment administration itself. To examine this, the results of SPT and TST 
were plotted against these factors (see Appendix 2). A negative correlation with SPT results 
and the time between treatment and testing can be seen to some extent, but a clear trend 
cannot be deduced from TST. Hence, this does not provide an explanation for the large 
variation of TST results.  
The final goal of this study was to further explore the effects of ketamine and N2O on 
previously observed shared molecular markers, but in an animal model of depression. This 
study demonstrates that N2O significantly upregulates Dusp1, Dusp6, Arc and Nr4a1 mRNA 
expression in the vmPFC after a 1-hour treatment and following 1-hour recovery period. 
Dusp5 levels were not significantly changed. Ketamine did not produce similar results in any 
of the targets. The variation in qPCR results is quite high, which could be due to purity of 
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mRNA varying from sample to sample, and the sample size being small (n = 4-5). From this 
study by itself, it is not possible to say whether the lack of antidepressant effects from 
ketamine is due to this specific dose not producing such robust antidepressant effects as N2O, 
and thus we see no changes in mRNA markers, or if ketamine just does not affect these 
markers in question. This dose of ketamine was chosen because it has often been shown to 
produce rapid antidepressant effects (Beurel et al., 2011; Li et al., 2010; Maeng et al., 2008), 
which contradicts the former. Additionally, ketamine did significantly increase saccharin 
preference in this study. However, the latter option also conflicts with not only our previous 
mRNA sequencing results (see Introduction; Rozov et al., unpublished data) but with other 
studies as well. A single dose of ketamine has been shown to transiently upregulate Arc in the 
PFC 1 hour after administration (Kohtala et al., 2019), with levels returning to baseline after 
6 hours (Li et al., 2010). Ketamine also normalizes the upregulated protein levels of DUSP1 
at 30 minutes and 72 hours after injection, and the downregulated phosphorylation of 
MAPK3 30 minutes after injection in the anterior cingulate cortex of a chronic pain induced 
model of depression (Humo et al., 2020). Thus, the results from this study differ from the 
results of most previous studies in two ways: 1) ketamine did not produce any molecular 
changes in these markers, and 2) Dusp levels are increased by N2O, not brought back to 
control levels as has been shown with both ketamine and traditional antidepressants. Even 
still, N2O treatment did partly produce similar effects to ones previously reported with rapid-
acting antidepressants. Both Arc and Nr4a1 expression was increased (Choi et al., 2015; 
Kohtala et al., 2019; Li et al., 2010), although upregulated Nr4a1 has only been demonstrated 
in vitro (Choi et al., 2015). Additionally, our previous mRNA sequencing study showed 
upregulation of these target markers by N2O (Rozov et al., unpublished data), just as in this 
study.  
Interestingly the molecular markers showed no significant changes between control and 
CORT VEH groups. Previous studies have shown that Dusps and Nr4a1 are upregulated in 
animal models of depression, although the results vary depending on brain region and method 
used to create the model (Duric et al., 2010; Gourley, Wu, & Taylor, 2008; Jeanneteau et al., 
2018). Arc has been found to be downregulated in the frontal cortex and CA1 area of the 
hippocampus after chronic mild stress and in a genetic animal model of depression (Elizalde 
et al., 2010). MAPK pathway inhibitors cause depressive-like behavior (Duman et al., 2007; 
Duric et al., 2010), the phosphorylation of MAPKs is reduced in depressed patients and 
animal models of depression (Dwivedi et al., 2001; Meller et al., 2003) and MAPKs and 
 31 
DUSPs are known to function in a negative feedback loop. Based on this it would be 
expected that if MAPK activity has been decreased for a longer time, then DUSPs are not 
upregulated either, as is the case in this study. Nonetheless, MAPK levels were not measured 
here, so no conclusions regarding this can be made. Furthermore, inhibited MAPK activity is 
a common finding among depressed patients and animal models, where it has arguably been 
this way for a longer time. Even still, Dusp expression is upregulated in these cases. This 
would suggest that Dusps are sustained by not only MAPKs, but other mechanisms as well, 
which keeps MAPK phosphorylation levels low. Indeed, the relationship between DUSPs and 
MAPKs can be regulated differently depending on the condition of specific cells and 
networks. MAPK3 can trigger DUSP1 proteolysis via the ubiquitin-proteasome pathway, 
hence achieving a positive feedback loop by decreasing its phosphatase activity (Lin et al., 
2003). Therefore, depending on the situation, DUSP activity can be modulated in either 
direction by the MAPK pathway. Another level of complexity is created by the fact that 
DUSPs are not only regulated on an mRNA level (Pérez‐Sen et al., 2019). The results of this 
study could simply indicate that chronic CORT administration does not lead to these markers 
being regulated on a transcriptional level, but rather on a post-translational or epigenetic level.  
It is still common to think of antidepressants as reversing a molecular problem or bringing 
specific protein levels back to normal, which then leads to rescue of depressive behavior. 
However, as the results of this study show, their actions are far more complex. N2O led to 
antidepressant-like behavioral effects and caused significant upregulation in selected mRNAs 
that modulate MAPKs, but it did not reverse expression of any of the targets tested, since the 
CORT VEH group did not differ from the control group. The observed difference of the 
results from this thesis to previous studies could stem from timing. It has been shown that 
rapid-acting antidepressants, specifically ketamine, cause cortical excitation (Kohtala et al., 
2019). Here it is shown in the form of Arc upregulation from N2O treatment. MAPK1/3 
phosphorylation is another sign of excitation, and it has been shown to be upregulated after 
treatment with both ketamine and N2O (Kohtala et al., 2019; Li et al., 2010). However, this 
upregulation is transient, and soon after phases into downregulation. Excitation of the cortex 
has also been shown to lead to endogenous BDNF release, and BDNF is necessary for Dusp1 
mRNA induction (Jeanneteau et al., 2010), further suggesting a possible need for neuronal 
excitation for the activation of these pathways. If N2O causes cortical excitation and thus 
MAPK pathway activation, this might cause a homeostatic need for Dusp levels to increase 
and lessen that activation, which ultimately leads to MAPK downregulation. Studies that 
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have shown downregulation of Dusps after rapid-acting antidepressant treatment have had 
brain tissue dissected for biochemical analyses either 7 hours after ketamine injection or after 
traditional antidepressant treatment – i.e. a longer period of time (Duric et al., 2010; Orozco-
Solis et al., 2017). In this study we dissected tissue for analysis 2 hours after treatment, so it 
could be that dissection was performed during the homeostatic rise of Dusps and that their 
expression may have been downregulated after. Arc is not only a marker of neuronal 
excitability, but also an important player in synaptic plasticity, because it regulates AMPAR 
endocytosis. Upregulation of Arc as seen in this study with N2O treatment may reflect the 
importance of homeostatic action as well. As mentioned previously, BDNF elevates Arc 
mRNA levels and this elevation is blocked by MAPK pathway inhibitors (Rao et al., 2006). 
This leads to an interesting contradiction, in that N2O treatment upregulates Arc in our study, 
where we assume MAPK activation to be lowered due to inhibition from upregulated Dusp 
expression.  
As discussed previously, Dusps and Nr4a1 are often upregulated in depressed patients. 
Additionally, acute stress causes transient MAPK pathway activation and Arc upregulation 
similarly to rapid-acting antidepressants. How do the phenomena demonstrated in this study 
then differ from the observations of depressed patients and acute stress? At first glance, the 
molecular response produced by N2O seems identical to what has been exhibited in depressed 
patients and animal models of depression. This indicates that the existing difference between 
these two states, rapid-acting antidepressant and depressed behavior, is more physiologically 
complex than just mRNA and protein levels. We hypothesize that the answer lies in the 
timing and homeostatic aspect of the brain’s responses. N2O and other rapid-acting 
antidepressants present a challenge for the brain, which then demands a homeostatic response. 
This response leads to synaptic changes, which have consistently been shown to be integral 
for sustained antidepressant effects. In support of this, many of the pathways and markers 
discussed in this thesis have straightforward connections to synaptic plasticity and 
microtubule organization. More importantly, this study is not the only one presenting 
contradicting results to previous research. Kodama et al. (2005) showed that Dusp1 and 
Dusp6 mRNA was increased in the frontal cortex of rats 1 hour after an electroconvulsive 
shock. Agreeing with the hypothesis presented in this thesis, no upregulation in either marker 
was observed at a later 6-hour time point.  
An important question to be answered in future research is what systemic neurobiological 
level changes does rapid-acting antidepressant treatment cause that lead to amelioration of 
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depressive symptoms even though the expression of the majority of these gene markers, at 
least 2 hours after treatment, are comparable to those seen in depressed patients and animal 
models of depression. Analysis of different levels of regulation of Dusps, such as protein and 
phosphorylation levels with western blotting should be incorporated into future studies. This 
thesis brought up the possible importance of timing when it comes to analysis of biochemical 
effects of rapid-acting antidepressants, hence the progression of MAPK pathway activation 
and simultaneously Dusp expression should be focused on. There exists little research 
particularly on Dusp activation kinetics in relation to rapid-acting antidepressants. N2O 
exhibits fast pharmacokinetics, which makes it a valuable tool for studying the time-
dependency of these phenomena. One approach to study this would be to regulate the MAPK 
pathway pharmacologically using compounds known to inhibit its function, such as 
PD184161, at different timepoints relative to N2O treatment. The most critical timepoints to 
compare would be injection of inhibitor immediately before and after treatment. Dissection 
times should also be varied, in order to confirm the speculation that the observed differences 
in Dusp regulation of this study to previous ones is due to different times between treatment 
and dissection. In order to further elucidate the relationship between cortical excitation and 
the behavioral and biochemical effects of rapid-acting antidepressants, 
electroencephalography (EEG) should be used for proper verification of excitation and 
observation of how the brain responds. This would allow analysis of the phenomenon on a 
more integrated level, especially when EEG events are compared with biochemical analyses 
from different timepoints.  
In future studies corticosterone levels circulating in the blood should be measured. Though 
measurement of drinking volumes can give some reference on the corticosterone amount each 
mouse has ingested, there are still factors that can affect how much makes it into the 
circulation. Measuring corticosterone directly combats this and would allow for better 
analysis of the correlational relationship between depressive behavior and amount of 
corticosterone the mouse was exposed to. One limitation of this study is the fact that 
corticosterone was dissolved in ethanol. The final concentration of ethanol was only 1% and 
it was controlled for by having the control group drink tap water with the same concentration 
of ethanol. Nonetheless, this results in nondescript unknowns possibly affecting the 
biochemistry of the brain and behavior. Corticosterone hemisuccinate could be used instead 
to avoid this, since it is less hydrophobic and can be dissolved in plain tap water. However, 
this does not necessarily erase the problem of introducing another foreign chemical into the 
 34 
experimental design. This might still be a better option, since it is well-known that ethanol 
greatly affects the brain. Another significant limitation of this study is the fact that there was 
no proper control group for the effects of N2O. N2O was administered in gas form and the 
mice were placed in a novel box for the duration of treatment. The novelty of both incoming 
air pressure and a new environment can greatly affect the physiology and subsequently the 
behavior of these mice. Hence, this form of administration should be controlled for by having 
a separate cohort of animals in the same environment being administered a control gas such 
as ambient air. Previous studies by our research group have shown that this does not 
significantly impact the biochemistry or behavior of mice (Kohtala et al., 2019; Rozov et al., 
unpublished data). Still, it does not change the fact that the lack of this control group in the 
present study makes it difficult to analyze the results confidently. Thankfully, this is a 
problem that can and should be fixed in future studies. 
This thesis aimed to explore the shared behavioral and biochemical effects of rapid-acting 
antidepressants ketamine and N2O in a chronic CORT-induced animal model of depression. 
This study has high novelty value, due to the study of N2O in a potential mouse model of 
depressive behavior. These preliminary results suggest that N2O could be a suitable candidate 
for rapid treatment of depression, since it reversed anhedonia observed in SPT. The 
antidepressant-like effects of N2O were accompanied by significant upregulation of Arc, 
Dusp1, Dusp6 and Nr4a1. No notable effects in target mRNAs were observed by sole chronic 
CORT administration or by ketamine treatment. This study produced both similarities and 
differences in results to previous research. Differences in time between treatment and tissue 
dissection is presented here as the possible cause of conflicting molecular results, particularly 
the ones observed in Dusp expression. We suggest that the action of rapid-acting 
antidepressants, in this study mostly N2O, is based on a homeostatic response of the brain to a 
presented challenge. Here this challenge would be cortical excitation previously been shown 
to be caused by N2O, which leads to activation of pathways such as MAPK and subsequent 
Arc, Dusp and Nr4a1 signaling. The level of expression of these molecular markers would 
then depend on which phase this response is in. While the chronic CORT-induced animal 
model demonstrated some behaviors typical of a depressive-like phenotype, it did not lead to 
any changes in the measured mRNA targets. This should be studied in more detail, since it 
contradicts data gathered from other animal models of depression and depressed patients. 
Furthermore, future studies would benefit from detailed validation of this model due to its 
potential in controlling for behavioral variability and thus reducing the number of animals 
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needed for preclinical research. Overall, if the findings of this thesis are replicated, it could be 
one of the first steps in the search for the mechanisms underlying the potential antidepressant 
effect of N2O, how these molecular markers are related to its action and how the actions of 
ketamine differ from these.      
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APPENDICES 
Appendix 1: Details of all statistical analyses  
 
 
 
 
Figure 5 n Statistical test Significance
A Coat assessment  n = 5, 5, 5, 5 Kruskal-Wallis one-way ANOVA H(3) = 10.51 p = 0.0006
NO CORT vs. CORT LOW n = 5, 5 Dunn's post hoc test ns p = 0.3523
NO CORT vs. CORT HIGH n = 5, 5 Dunn's post hoc test ** p = 0.0036
CORT LOW vs. CORT HIGH n = 5, 5 Dunn's post hoc test ns p = 0.2819
B Saccharin preference test n = 5, 5, 5, 5 Kruskal-Wallis one-way ANOVA H(3) = 7.768 p = 0.0117
NO CORT vs. CORT LOW n = 5, 5 Dunn's post hoc test ns p = 0.8639
NO CORT vs. CORT HIGH n = 5, 5 Dunn's post hoc test * p = 0.0172
CORT LOW vs. CORT HIGH n = 5, 5 Dunn's post hoc test ns p = 0.2673
C Duration of immobility in TST n = 5, 5, 5, 5 One-way ANOVA F(2, 12) = 2.160 p = 0.1580
Figure 6 n Statistical test Significance
A Weight changes n = 11, 9, 9, 10 Kruskal-Wallis one-way ANOVA H(4) = 11.494 p = 0.009333
NO CORT VEH vs. CORT VEH n = 11, 9 Dunn's post hoc test ns p = 0.11877
NO CORT VEH vs. CORT KET n = 11, 9 Dunn's post hoc test * p = 0.01078
NO CORT VEH vs. CORT N2O n = 11, 10 Dunn's post hoc test ns p = 0.09074
CORT VEH vs. CORT KET n = 9, 9 Dunn's post hoc test ns p = 1.0
CORT VEH vs. CORT N2O n = 9, 10 Dunn's post hoc test ns p = 1.0
CORT KET vs. CORT N2O n = 9, 10 Dunn's post hoc test ns p = 1.0
B Nest assessment n = 11, 9, 9, 10 Kruskal-Wallis one-way ANOVA H(4) = 2.61 p = 0.4551
C Coat assessment n = 11, 9, 9, 10 Kruskal-Wallis one-way ANOVA H(4) = 25.24 p < 0.0001
NO CORT VEH vs. CORT VEH n = 11, 9 Dunn's post hoc test **** p < 0.0001
NO CORT VEH vs. CORT KET n = 11, 9 Dunn's post hoc test ** p = 0.0017
NO CORT VEH vs. CORT N2O n = 11, 10 Dunn's post hoc test *** p < 0.0001
CORT VEH vs. CORT KET n = 9, 9 Dunn's post hoc test ns p = 1.0
CORT VEH vs. CORT N2O n = 9, 10 Dunn's post hoc test ns p = 1.0
CORT KET vs. CORT N2O n = 9, 10 Dunn's post hoc test ns p = 1.0
D Saccharin preference test n = 11, 9, 9, 10 One-way ANOVA F(3, 35) = 8.001 p = 0.000343
NO CORT VEH vs. CORT VEH n = 11, 9 Tukey post hoc test *** p = 0.00035
NO CORT VEH vs. CORT KET n = 11, 9 Tukey post hoc test ns p = 0.9102
NO CORT VEH vs. CORT N2O n = 11, 10 Tukey post hoc test ns p = 0.8304
CORT VEH vs. CORT KET n = 9, 9 Tukey post hoc test ## p = 0.00390
CORT VEH vs. CORT N2O n = 9, 10 Tukey post hoc test ## p = 0.00463
CORT KET vs. CORT N2O n = 9, 10 Tukey post hoc test ns p = 0.9985
E Duration of immobility in TST n = 11, 9, 9, 10 One-way ANOVA F(3, 35) = 3.119 p = 0.0383
NO CORT VEH vs. CORT VEH n = 11, 9 Tukey post hoc test ns p = 0.2938
NO CORT VEH vs. CORT KET n = 11, 9 Tukey post hoc test ns p = 0.3114
NO CORT VEH vs. CORT N2O n = 11, 10 Tukey post hoc test ns p = 0.8776
CORT VEH vs. CORT KET n = 9, 9 Tukey post hoc test ns p = 0.99998
CORT VEH vs. CORT N2O n = 9, 10 Tukey post hoc test ns p = 0.08373
CORT KET vs. CORT N2O n = 9, 10 Tukey post hoc test ns p = 0.09042
F Latency to immobility in TST n = 11, 9, 9, 10 One-way ANOVA F(3, 35) = 2.719 p = 0.0593
NO CORT VEH vs. CORT VEH n = 11, 9 Tukey post hoc test ns p = 0.3811
NO CORT VEH vs. CORT KET n = 11, 9 Tukey post hoc test ns p = 0.0865
NO CORT VEH vs. CORT N2O n = 11, 10 Tukey post hoc test ns p = 0.9984
CORT VEH vs. CORT KET n = 9, 9 Tukey post hoc test ns p = 0.8586
CORT VEH vs. CORT N2O n = 9, 10 Tukey post hoc test ns p = 0.4906
CORT KET vs. CORT N2O n = 9, 10 Tukey post hoc test ns p = 0.1327
 42 
 
  
Figure 7 n Statistical test Significance
A Dusp1 n = 4, 4, 5, 5 One-way ANOVA F(3, 14) = 4.260 p = 0.0247
NO CORT VEH vs. CORT VEH n = 4, 4 Tukey post hoc test ns p = 0.9517
NO CORT VEH vs. CORT KET n = 4, 5 Tukey post hoc test ns p > 0.9999
NO CORT VEH vs. CORT N2O n = 4, 5 Tukey post hoc test ns p = 0.0883
CORT VEH vs. CORT KET n = 4, 5 Tukey post hoc test ns p = 0.9459
CORT VEH vs. CORT N2O n = 4, 5 Tukey post hoc test # p = 0.0323
CORT KET vs. CORT N2O n = 5, 5 Tukey post hoc test ns p = 0.066
B Dusp5 n = 4, 4, 5, 5 One-way ANOVA F(3, 14) = 0.8154p = 0.5065
C Dusp6 n = 4, 4, 5, 5 One-way ANOVA F(3, 14) = 4.277 p = 0.0244
NO CORT VEH vs. CORT VEH n = 4, 4 Tukey post hoc test ns p = 0.9742
NO CORT VEH vs. CORT KET n = 4, 5 Tukey post hoc test ns p = 0.8112
NO CORT VEH vs. CORT N2O n = 4, 5 Tukey post hoc test * p = 0.029
CORT VEH vs. CORT KET n = 4, 5 Tukey post hoc test ns p = 0.9694
CORT VEH vs. CORT N2O n = 4, 5 Tukey post hoc test ns p = 0.0656
CORT KET vs. CORT N2O n = 5, 5 Tukey post hoc test ns p = 0.1124
Figure 8 n Statistical test Significance
A Arc n = 4, 4, 5, 5 One-way ANOVA F(3, 14) = 4.105 p = 0.0277
NO CORT VEH vs. CORT VEH n = 4, 4 Tukey post hoc test ns p = 0.9174
NO CORT VEH vs. CORT KET n = 4, 5 Tukey post hoc test ns p= 0.9175
NO CORT VEH vs. CORT N2O n = 4, 5 Tukey post hoc test * p = 0.0321
CORT VEH vs. CORT KET n = 4, 5 Tukey post hoc test ns p > 0.9999
CORT VEH vs. CORT N2O n = 4, 5 Tukey post hoc test ns p = 0.1086
CORT KET vs. CORT N2O n = 5, 5 Tukey post hoc test ns p = 0.0783
B NR4A1 n = 4, 4, 5, 5 One-way ANOVA F(3, 14) = 4,904 p = 0.0156
NO CORT VEH vs. CORT VEH n = 4, 4 Tukey post hoc test ns p = 0.9536
NO CORT VEH vs. CORT KET n = 4, 5 Tukey post hoc test ns p = 0.7812
NO CORT VEH vs. CORT N2O n = 4, 5 Tukey post hoc test * p = 0.0182
CORT VEH vs. CORT KET n = 4, 5 Tukey post hoc test ns p = 0.9773
CORT VEH vs. CORT N2O n = 4, 5 Tukey post hoc test ns p = 0.0504
CORT KET vs. CORT N2O n = 5, 5 Tukey post hoc test ns p = 0.079
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Appendix 2: Saccharin preference test and tail suspension test results plotted against 
time. Total immobility time in TST of the CORT N2O group against time of treatment (A) 
and time between treatment and TST (B). Total immobility time in TST of the CORT KET 
group against time of treatment (C) and time between treatment and TST (D). SPT results of 
the CORT N2O (E) and CORT KET (F) group against time between treatment and start of 
SPT. Data plotted as individual values with a fitted linear curve. TST: tail suspension test, 
SPT: saccharin preference test.  
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